Our vision is to democratize cell-based immunotherapies for all cancer patients.
About Us
Cell BioEngines, Inc., is a clinical-stage biotech company focused on developing 'off-the-shelf' allogenic cell therapies as 'drugs' to turn all cancers into curable diseases. The company leverages its proprietary Stem-SPACE™ platform technology to produce clinical-grade cells at economies of scale.
A Delaware C corporation established in December 2022, the company's revolutionary science includes single cell discoveries from Harvard Medical School, and in-licensing manufacturing process technology from Icahn School of Medicine at Mount Sinai.
Our Strategy
We Develop Cell-based Products Both Within Our Company and Through Our Partner Company
Our Business Model
3-Step Product Innovation System
Allows Diversified Development of Multiple Programs Spanning Several Large Therapeutic Markets
Our MANUFACTURING Approach
Manufacturing Platform
Stem Cells Expansion and Differentiation to Manufacture Potent Cells for Clinical Use
Product Pipeline
Cellular Immunotherapy Product Candidates to Transform Medicine and Healthcare
Our Goals
More than 1 disease at a time
More than 1 disease at a time
More than 1 disease at a time
We are therapeutic area agnostic which allows us maximum flexibility to focus on advancing cutting-edge cell-based immuno-therapeutics approaches in oncology across multiple types of solid cancer.
Decrease time to development
More than 1 disease at a time
More than 1 disease at a time
Allows us to pursue a broad range of products and product candidates with high clinical and commercial potential. This broad and deep diversification lowers the time to development and overall risk profile of the company.
Lower translational costs
More than 1 disease at a time
Lower translational costs
Low cost manufacturing enables us to act quickly to seize time-sensitive opportunities and provides us with a wider range of options from which to select the most ideal financial structure for each product.